Vertex Pharmaceuticals Reports Business and Program Updates Ahead of Investor Meetings in January 2026

Vertex Pharmaceuticals announced business and program updates ahead of investor meetings. The company's CEO, Reshma Kewalramani, highlighted strong commercial execution and R&D progress in 2025, setting up for continued growth in 2026. Vertex is expanding its commercial reach, advancing the emerging renal franchise, and progressing its clinical pipeline. The company's cystic fibrosis treatment, ALYFTREK, is now approved in several countries, and Vertex plans to submit for approvals in patients under two years of age. Vertex also advanced next-generation CFTR modulators and a CFTR mRNA therapeutic.